Filing Flows › Zai Lab (ZLAB) › Q3 2026 › vs Q3 2025
Zai Lab (ZLAB) Q3 2026 vs Q3 2025 (year over year)
Zai Lab's revenue fell $7.9M (-7%) from $116M in Q3 2025 to $108M in Q3 2026. The biggest changes: ZEJULA −$10.1M (-24%); NUZYRA +$5.7M (+37%); OPTUNE −$4.8M (-38%).
Zai Lab, Q3 2026: revenue $108M (-7% year over year), operating margin -58.2%, net loss $46.1M, operating cash flow −$57.9M. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| ZEJULA | $32.3M | $42.4M | −$10.1M | -24% |
| VYVGART / VYVGART Hytrulo | $24.1M | $27.7M | −$3.7M | -13% |
| NUZYRA | $21.1M | $15.4M | $5.7M | +37% |
| QINLOCK | $8.8M | $8.9M | −$72K | -0.8% |
| XACDURO | $8.4M | $6.4M | $2.0M | +31% |
| OPTUNE | $7.8M | $12.7M | −$4.8M | -38% |
| AUGTYRO | $2.8M | $1.7M | $1.1M | +68% |
| KarXT | $2.0M | $0 | $2.0M | — |
| Other revenues | $856K | $826K | $30K | +4% |
| Revenue | $108M | $116M | −$7.9M | -7% |
| Other income, net | $15.0M | $12.9M | $2.1M | +16% |
| Income tax benefit | $1.9M | $0 | $1.9M | — |
| Net loss | $46.1M | $36.0M | $10.2M | +28% |
| Costs & expenses | $171M | $165M | $6.3M | +4% |
| Operating costs | $171M | $165M | $6.3M | +4% |
| Cost of revenue | $51.3M | $46.8M | $4.5M | +10% |
| Research & development | $49.8M | $47.9M | $1.9M | +4% |
| SG&A | $70.1M | $70.1M | −$35K | 0% |
| Operating cash sources | $73.3M | $52.9M | $20.4M | +39% |
| Depreciation & amortization | $4.4M | $3.9M | $510K | +13% |
| Share-based compensation | $11.0M | $16.9M | −$5.9M | -35% |
| Cash used in operations | $57.9M | $32.0M | $25.8M | +81% |
| Net loss absorbed | $46.1M | $36.0M | $10.2M | +28% |
| Working capital & other | $27.1M | $16.9M | $10.2M | +61% |
Questions
How much did Zai Lab's revenue grow year over year in Q3 2026?
Zai Lab's revenue fell $7.9M (-7%) from $116M in Q3 2025 to $108M in Q3 2026.
What drove Zai Lab's revenue change in Q3 2026?
ZEJULA −$10.1M (-24%); NUZYRA +$5.7M (+37%); OPTUNE −$4.8M (-38%).